Ironwood Pharmaceuticals, Inc. [NASDAQ:IRWD]: Analyst Rating and Earnings
Pro stock traders frequently make sure to pay attention what expert market analysts are saying about a potential stock buy. Regarding Ironwood Pharmaceuticals, Inc. [IRWD] right now, the most recent ratings from Wall St. analysts that we can see right now is regarding the quarter that’s slated to end in December. On average, stock market experts give IRWD an Outperform rating. Its stock price has been found in the range of 7.59 to 17.74. This is compared to its latest closing price of $9.80.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Ironwood Pharmaceuticals, Inc. [IRWD] is sitting at 2.50. This is compared to 1 month ago, when its average rating was 2.50.
For the quarter ending in Mar-19 Ironwood Pharmaceuticals, Inc. [IRWD] generated $0.07 billion in sales. That’s 15.34% lower than the average estimate of $0.08 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.
Keep your eyes peeled for the next scheduled financial results to be made public for this company, which are scheduled to be released on Mon 5 Aug (In 82 Days).
Fundamental Analysis of Ironwood Pharmaceuticals, Inc. [IRWD]
Now let’s turn to look at profitability: with a current Operating Margin for Ironwood Pharmaceuticals, Inc. [IRWD] sitting at -29.50 and its Gross Margin at +88.21, this company’s Net Margin is now -86.20%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -32.59, and its Return on Invested Capital has reached -109.80%. Its Return on Assets is -60.22.
Similarly, its Total Debt to Total Capital is 190.26, while its Total Debt to Total Assets stands at 124.66.
What about valuation? This company’s Enterprise Value to EBITDA is -21.44. The Enterprise Value to Sales for this firm is now 5.45, and its Total Debt to Enterprise Value stands at 0.23.
Shifting the focus to workforce efficiency, Ironwood Pharmaceuticals, Inc. [IRWD] earns $673,085 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 4.25 and its Total Asset Turnover is 0.74. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.23 and its Current Ratio is 2.23. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Ironwood Pharmaceuticals, Inc. [IRWD] has 157.97M shares outstanding, amounting to a total market cap of $1.55B. Its stock price has been found in the range of 7.59 to 17.74. At its current price, it has moved by -45.11% from its 52-week high, and it has moved 28.30% from its 52-week low.
This stock’s Beta value is currently 1.85, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 34.02. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Ironwood Pharmaceuticals, Inc. [IRWD] a Reliable Buy?
Shares of Ironwood Pharmaceuticals, Inc. [IRWD], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.